{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:25:25Z","timestamp":1787239525584,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Belarus Ministry of Health","award":["7\/2014"],"award-info":[{"award-number":["7\/2014"]}]},{"name":"Belarus Ministry of Health","award":["03.17"],"award-info":[{"award-number":["03.17"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>We report, in brief, the results of a phase I, non-randomized study of idiotypic DNA vaccination in patients with B-cell non-Hodgkin\u2019s lymphoma (ISRCTN31090206). The DNA sequence of lymphoma-derived immunoglobulin variable regions was used as a tumor-specific antigen fused to the potato virus X coat protein. A conjugate of plasmid DNA with polyethylenimine was used for the intramuscular injections, followed by a boost with an oral live-attenuated Salmonella vaccine carrying the same plasmid. The patients with a complete or partial response to previous chemotherapy received one or two courses of vaccination, including four injections at monthly intervals. The vaccine was well tolerated, with low-grade adverse events. The T-cell immune responses were assessed by ELISpot, at last vaccine, one week and one month post-vaccination, and were detected in 11\/14 (78.6%) of the patients. In cases of progression requiring chemotherapy, or the presence of a positive MRD after the first course of vaccination, the patients underwent a second course of vaccination. At the end point, 6\/19 vaccinated patients had disease stabilization, while 13\/19 were in complete remission. The overall survival was 100% at follow-up, of a median of 2.3 years.<\/jats:p>","DOI":"10.3390\/cancers14143298","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T09:41:10Z","timestamp":1657100470000},"page":"3298","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6964-3635","authenticated-orcid":false,"given":"Alexander","family":"Meleshko","sequence":"first","affiliation":[{"name":"Belarusian Research Center for Pediatric Oncology and Hematology, 223053 Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadzeya","family":"Piatrouskaya","sequence":"additional","affiliation":[{"name":"Oncology Department of Czech Krumlov Hospital, 38101 Cesky Krumlov, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Vashkevich","sequence":"additional","affiliation":[{"name":"Belarusian Research Center for Pediatric Oncology and Hematology, 223053 Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzmitry","family":"Lutskovich","sequence":"additional","affiliation":[{"name":"Belarusian Research Center for Pediatric Oncology and Hematology, 223053 Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Cancer Sciences, ISMIB, University of Liverpool, Liverpool 11341, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-3005","authenticated-orcid":false,"given":"Dmitri","family":"Dormeshkin","sequence":"additional","affiliation":[{"name":"Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus, 220141 Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Savelyeva","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Cancer Sciences, ISMIB, University of Liverpool, Liverpool 11341, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikalai","family":"Katsin","sequence":"additional","affiliation":[{"name":"Vitebsk Regional Cancer Centre, 210603 Vitebsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"ref_1","unstructured":"Oceanov, A.I., Moiseev, P.I., Levin, L.F., Evmenenko, A.A., and Ipatiy, T.B. (2020). Cancer in Belarus: Figures and Facts: Analysis of Data of the Belarusian Cancer Register for 2010\u20132019, N. N. Alexandrov National Cancer Centre."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11912-012-0255-7","article-title":"Active Immunotherapy: Current State of the Art in Vaccine Approaches for NHL","volume":"14","author":"Palomba","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1158\/0008-5472.CAN-05-4233","article-title":"Phase I Trial of a Novel Intradermal Idiotype Vaccine in Patients with Advanced B-Cell Lymphoma: Specific Immune Responses despite Profound Immunosuppression","volume":"66","author":"Bertinetti","year":"2006","journal-title":"Cancer Res."},{"key":"ref_5","first-page":"801","article-title":"Idiotype Vaccines for Lymphoma Therapy. Expert Rev","volume":"10","author":"Villanueva","year":"2011","journal-title":"Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00262-015-1703-7","article-title":"Idiotypic DNA Vaccination for the Treatment of Multiple Myeloma: Safety and Immunogenicity in a Phase I Clinical Study","volume":"64","author":"McCann","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Thomas, S.K., Cha, S.-C., Smith, D.L., Kim, K.H., Parshottam, S.R., Rao, S., Popescu, M., Lee, V.Y., Neelapu, S.S., and Kwak, L.W. (2018). Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma with DNA Vaccines Encoding Antigen-Chemokine Fusion: Study Protocol. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4094-2"},{"key":"ref_8","first-page":"5845","article-title":"Immunogenicity of a Plasmid DNA Vaccine Encoding Chimeric Idiotype in Patients with B-Cell Lymphoma","volume":"62","author":"Timmerman","year":"2002","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/eji.201242410","article-title":"Enhancement of Plasmid DNA Immunogenicity with Linear Polyethylenimine","volume":"42","author":"Grant","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jconrel.2021.01.005","article-title":"Novel Lipid Combination for Delivery of Plasmid DNA to Immune Cells in the Spleen","volume":"330","author":"Kimura","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Graham, B.S., Enama, M.E., Nason, M.C., Gordon, I.J., Peel, S.A., Ledgerwood, J.E., Plummer, S.A., Mascola, J.R., Bailer, R.T., and Roederer, M. (2013). DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after RAd5 Boost in a Randomized Clinical Trial. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059340"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/vaccines3040940","article-title":"Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery","volume":"3","author":"Lin","year":"2015","journal-title":"Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1080\/21645515.2017.1285477","article-title":"Phase I Clinical Trial of Idiotypic DNA Vaccine Administered as a Complex with Polyethylenimine to Patients with B-Cell Lymphoma","volume":"13","author":"Meleshko","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/90816","article-title":"Plant Viral Genes in DNA Idiotypic Vaccines Activate Linked CD4+ T-Cell Mediated Immunity against B-Cell Malignancies","volume":"19","author":"Savelyeva","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"ref_15","first-page":"8","article-title":"V Cloning of Variable Fragments of Tumor Immunoglobulin, Assembling and Expressing of Human SCFV Protein in E. Coli for Anti-Idiotype Vaccination","volume":"35","author":"Meleshko","year":"2013","journal-title":"Exp. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/protein\/6.8.989","article-title":"An Improved Linker for Single-Chain Fv with Reduced Aggregation and Enhanced Proteolytic Stability","volume":"6","author":"Whitlow","year":"1993","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"763086","DOI":"10.3389\/fimmu.2021.763086","article-title":"DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_18","unstructured":"Hackworth, J. (2006). DNA Vaccines: Methods and Protocols, Humana Press Inc.. [2nd ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.gt.3301516","article-title":"Prolonged Organ Retention and Safety of Plasmid DNA Administered in Polyethylenimine Complexes","volume":"8","author":"Oh","year":"2001","journal-title":"Gene Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00262-020-02652-2","article-title":"Multi-Antigen DNA Vaccine Delivered by Polyethylenimine and Salmonella Enterica in Neuroblastoma Mouse Model","volume":"69","author":"Stegantseva","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2011.04.013","article-title":"V Prognostic Value of MRD-Dynamics in Childhood Acute Lymphoblastic Leukemia Treated According to the MB-2002\/2008 Protocols","volume":"35","author":"Meleshko","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of Minimal Residual Disease by Ig\/TCR Gene Rearrangements: Guidelines for Interpretation of Real-Time Quantitative PCR Data","volume":"21","author":"Cazzaniga","year":"2007","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17650\/1818-8346-2015-10-4-15-24","article-title":"Treatment of B-Cells Non-Hodgkin Lymphomas with Combined Immunochemotherapy: Ability to Treatment Optimization","volume":"10","author":"Smirnova","year":"2015","journal-title":"Oncohematology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2012.12.026","article-title":"Salmonella SL7207 Application Is the Most Effective DNA Vaccine Delivery Method for Successful Tumor Eradication in a Murine Model for Neuroblastoma","volume":"331","author":"Berger","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_25","first-page":"101","article-title":"Engineering DNA Vaccines That Include Plant Virus Coat Proteins. Biotechnol","volume":"20","author":"Savelyeva","year":"2003","journal-title":"Genet. Eng. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-10-3","article-title":"Improvement of Different Vaccine Delivery Systems for Cancer Therapy","volume":"10","author":"Bolhassani","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_27","first-page":"163","article-title":"Polyethylenimine-Mediated Gene Delivery to the Lung and Therapeutic Applications","volume":"2","author":"Conese","year":"2009","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-2.14473","article-title":"Conjugation of New DNA Vaccine with Polyethylenimine Induces Cellular Immune Response and Tumor Regression in Neuroblastoma Mouse Model","volume":"42","author":"Stegantseva","year":"2020","journal-title":"Exp. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/17425247.2013.744964","article-title":"Novel Polyethylenimine-Derived Nanoparticles for in Vivo Gene Delivery","volume":"10","author":"Patnaik","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s13277-015-4061-3","article-title":"An Orally Administered DNA Vaccine Targeting Vascular Endothelial Growth Factor Receptor-3 Inhibits Lung Carcinoma Growth","volume":"37","author":"Chen","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1248\/bpb.33.174","article-title":"Orally Administered DNA Vaccine Delivery by Attenuated Salmonella Typhimurium Targeting Fetal Liver Kinase 1 Inhibits Murine Lewis Lung Carcinoma Growth and Metastasis","volume":"33","author":"Zuo","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Niethammer, A.G., Lubenau, H., Mikus, G., Hohmann, N., Leowardi, C., Beckhove, P., Akhisaroglu, M., Ge, Y., Springer, M., and Grenacher, L. (2012). Double-Blind, Placebo-Controlled First in Human Study to Investigate an Oral Vaccine Aimed to Elicit an Immune Reaction against the VEGF-Receptor 2 in Patients with Stage IV and Locally Advanced Pancreatic Cancer. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-361"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1303584","DOI":"10.1080\/2162402X.2017.1303584","article-title":"A Phase 1 Trial Extension to Assess Immunologic Efficacy and Safety of Prime-Boost Vaccination with VXM01, an Oral T Cell Vaccine against VEGFR2, in Patients with Advanced Pancreatic Cancer","volume":"7","author":"Hohmann","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"eabe3348","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-Specific Cytolytic CD4 T Cells Mediate Immunity against Human Cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci. Adv."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3298\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:43:30Z","timestamp":1760139810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":34,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14143298"],"URL":"https:\/\/doi.org\/10.3390\/cancers14143298","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}